New Tamoxifen-Like drug tested for stubborn hormone cancers
NCT ID NCT01273168
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tested an experimental drug called Z-Endoxifen in 40 adults with hormone receptor-positive cancers (like breast, ovarian, or desmoid tumors) that had stopped responding to standard treatments. Z-Endoxifen is a direct form of tamoxifen's active ingredient, bypassing the need for liver conversion. The main goal was to check safety and find the right dose, while also seeing if it could slow tumor growth.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Z-Endoxifen (an active form of tamoxifen)
- What this could lead to
- If it works, this could provide a treatment option for people with hormone-positive cancers that no longer respond to standard therapies.
- What could go wrong
- This is an early Phase 1 trial with only 40 participants, so safety and dosing are the main focus—not yet proof of effectiveness. The drug may cause side effects or fail to shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DESMOID are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New hope for rare tumor patients: chemo delivered directly to desmoid growths
- New imaging method may spot tumor growth earlier after freezing treatment
- Stress ball squeeze eases pap smear pain, study finds
- New hope for rare tumor patients: AL102 drug trial launches
- Can a Stress-Management program help young cancer patients cope?
- New drug FOG-001 takes on Hard-to-Treat cancers